Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

FDA approves Sage and Biogen drug for postpartum depression, rejects it for major depressive disorder

by Gina Vitale
August 19, 2023 | A version of this story appeared in Volume 101, Issue 27

 

The US Food and Drug Administration has approved Zurzuvae (zuranolone)—the result of a collaboration between Biogen and Sage Therapeutics—as the first oral drug to treat postpartum depression. But the FDA rejected the small molecule for use in major depressive disorder, sending Sage’s stock tanking. In a second-quarter earnings report published after the agency’s decision, Sage CEO Barry Greene said the company is evaluating “pipeline prioritization” and “a workforce reorganization.”

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.